Trials of anti-CTLA-4 blockade-based therapy continued and several multicenter-based trials of Ipilimumab, alone or in combination with gp100-based immunization, confirmed anti-tumor activities of the anti-CTLA-4 antibody Ipilimumab alone, and most importantly, showed its effectiveness in improving survival of melanoma patients [41]. The gene discussed is CTLA4; the disease is neoplasm.